Table 2 Descriptive statistics, demographic characteristics, clinical and biochemistry results of the patients
x̄ ± SD | Median (Min–Max) | |
|---|---|---|
Features | ||
Age | 67 ± 16.9 | 70.5 (18–92) |
n | % | |
|---|---|---|
Gender | ||
Female | 50 | 42.4 |
Male | 68 | 57.6 |
HT | ||
(−) | 80 | 67.8 |
( +) | 38 | 32.2 |
DM | ||
(−) | 96 | 81.4 |
( +) | 22 | 18.6 |
CAD | ||
(−) | 105 | 89 |
( +) | 13 | 11 |
COPD | ||
(−) | 111 | 94.1 |
( +) | 7 | 5.9 |
Active malignancy | ||
(−) | 100 | 84.7 |
( +) | 18 | 15.3 |
Hematological malignancy | ||
(−) | 105 | 89 |
( +) | 13 | 11 |
Immunosuppressive usage | ||
(−) | 102 | 86.4 |
( +) | 16 | 13.6 |
Proven CAPA | ||
(−) | 108 | 91.5 |
( +) | 10 | 8.5 |
LFA (cut-off: 0.5) | ||
(−) | 103 | 87.3 |
( +) | 5 | 12.7 |
LFA (cut-off: 1.0) | ||
(–) | 116 | 98.3 |
( +) | 2 | 1.7 |
ELISA (cut-off: 0.5) | ||
(−) | 107 | 90.7 |
( +) | 11 | 9.3 |
ELISA (cut-off: 1.0) | ||
(−) | 113 | 95.8 |
( +) | 5 | 4.2 |
Last status | ||
Alive | 30 | 25.4 |
Exitus | 88 | 74.6 |
x̄ ± SD | Median (Min–Max) | |
|---|---|---|
Follow-up (days) | 26.82 ± 35.8 | 13 (2–207) |